This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479405/805-10-25-23

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingCostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Value of new stock classified as temporary equity issued during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent Milestone Obligation Accrued

+ References

No definition available.

+ Details

Name:	vera_ContingentMilestoneObligationAccrued
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License and collaborations.

+ References

No definition available.

+ Details

Name:	vera_LicenseAndCollaborationsLineItems
Namespace Prefix:	vera_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone payments payable.

+ References

No definition available.

+ Details

Name:	vera_MilestonePaymentsPayable
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Reduction In Contingent Future Development

+ References

No definition available.

+ Details

Name:	vera_ReductionInContingentFutureDevelopment
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Stock issued during period shares licensing payments in equity.

+ References

No definition available.

+ Details

Name:	vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity
Namespace Prefix:	vera_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock Issued During Period Shares Licensing Payments In Equity (value)

+ References

No definition available.

+ Details

Name:	vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue
Namespace Prefix:	vera_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Temporary equity stock shares issued during the period shares.

+ References

No definition available.

+ Details

Name:	vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares
Namespace Prefix:	vera_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AresTradingSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_EventAxis=vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_AgreementAxis=vera_AresAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_EventAxis=vera_AchievementOfSpecifiedCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_EventAxis=vera_RegulatoryApprovalInTheUSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_AgreementAxis=vera_AmplyxAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AmplyxAndNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_EventAxis=vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vera_AgreementAxis=vera_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=vera_SeriesCRedeemableConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licenses and Collaborations - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended		9 Months Ended	12 Months Ended
	Oct. 31, 2020	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
License and Collaborations [Line Items]
Research and development		$ 29,311		$ 16,231		$ 52,511	$ 41,340
Ares Trading S A [Member] \| Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable										$ 15,000
Ares Agreement [Member] \| Ares Trading S A [Member]
License and Collaborations [Line Items]
Milestone payments payable										25,000
Related party transaction, expenses from transactions with related party			$ 100		$ 1,100	200	$ 2,000
Ares Agreement [Member] \| Ares Trading S A [Member] \| Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable										176,500
Ares Agreement [Member] \| Ares Trading S A [Member] \| Achievement Of Specified Commercial Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable										515,000
Ares Agreement [Member] \| Ares Trading S A [Member] \| Regulatory Approval In The U.S [Member]
License and Collaborations [Line Items]
Milestone payments payable										$ 20,000
Amplyx Agreement [Member]
License and Collaborations [Line Items]
Milestone payments payable									$ 2,000
Acquisition cost									5,000
Research and development									7,000
Reduction in contingent future development								$ 7,000
Contingent milestone obligation accrued									$ 2,000
Company shares issued								$ 5,700
Amplyx Agreement [Member] \| Amplyx and Novartis [Member] \| Achievement of Various Clinical Development and Regulatory Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable		7,000				7,000
Novartis [Member] \| Amplyx and Novartis [Member] \| Achievement of Various Clinical Development and Regulatory Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable		$ 62,000				$ 62,000
Series C [Member] \| Ares Agreement [Member] \| Ares Trading S A [Member]
License and Collaborations [Line Items]
Temporary equity stock shares issued during the period shares	1,913,501
Temporary equity shares issued during the period value	$ 13,100
Common Class A [Member]
License and Collaborations [Line Items]
Company shares issued								283,034